MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

luno	17-18.	2022
Julie	1/-10.	ZUZZ

June 17-18, 2022		
AGENDA ITEM	PRESIDER/PRESENTER(s)	
lune 17, 2022		
Welcome & Introductions	Dr. Grace Lee (ACIP Chair)	
	Dr. Melinda Wharton (ACIP Executive Secretary, CDC	
Coronavirus Disease 2019 (COVID-19) Vaccines		
Introduction	Dr. Matthew Daley (ACIP, WG Chair)	
Epidemiology of COVID-19 in young children	Dr. Katherine Fleming-Dutra (CDC/NCIRD)	
Updates on vaccine effectiveness of COVID-19 vaccines in children and adolescents	Dr. Ruth Link-Gelles (CDC/NCIRD)	
Break		
Moderna COVID-19 vaccine (mRNA-1273): Safety, immunogenicity and efficacy in children ages 6 months through 5 years of age	Dr. Rituparna Das (Moderna)	
	Dr. Dill Crash er (Dfiner)	
years of age	Dr. Bill Gruber (Pfizer)	
mRNA COVID-19 vaccines in young children: Summary and Work Group interpretation	Dr. Sara Oliver (CDC/NCIRD)	
<u>Public Comment</u> Adjourn		
y, June 18, 2022		
Welcome & Introductions	Dr. Grace Lee (ACIP Chair)	
	Dr. Melinda Wharton (ACIP Executive Secretary, CDC	
Coronavirus Disease 2019 (COVID-19) Vaccines		
Introduction	Dr. Matthew Daley (ACIP, WG Chair)	
Implementation of pediatric vaccines	Dr. Kevin Chatham-Stephens (CDC/NCBDDD)	
Evidence to recommendation Framework: mRNA COVID-19 vaccine in young children	Dr. Sara Oliver (CDC/NCIRD)	
Clinical Considerations update Discussion	Dr. Elisha Hall (CDC/NCIRD)	
VOTE		
Moderna COVID-19 vaccine in children ages 6 months - 5 years	Dr. Sara Oliver (CDC/NCIRD)	
Pfizer-BioNTech COVID-19 vaccine in children ages 6 months - 4 years	Dr. Sara Oliver (CDC/NCIRD)	
Adjourn		
15		
Centers for Disease Control and Prevention		
Centers for Medicare and Medicaid Services		
Coronavirus disease 2019		
Evidence to Recommendations Framework		
Grading of Recommendations Assessment, Development and Evaluation		
Health Resources and Services Administration		
Indian Health Service		
National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]		
National Center for Immunization & Respiratory Diseases [of CDC/OID]		
National Center for Emerging and Zoonotic Diseases [of CDC/OID]		
Severe Acute Respiratory Syndrome Coronavirus 2		
World Health Organization		
COVID-19 Vaccine Safety Technical (VaST) Work Group		
Vaccine Effectiveness		
	Lacibua TEM Varianze Jacoba Varianze A introductions Consorvirus Disease 2019 (COVID-19) Vaccines Introduction Epidemiology of COVID-19 in young children Updates on vaccine effectiveness of COVID-19 vaccines in children and adolescents Brack Monan COVID-19 vaccine (mRNA-1273): Safety, immunogenicity and efficacy of BNT162b2 in children ages 6 months through 5 years of age. Safety, immunogenicity and efficacy of BNT162b2 in children ages 6 months through 4 difeores 7 genomes Monan COVID-19 vaccine in young children : Summary and Work Group interpretation Public Comment Agiourn Value 18.2022 Watcome & Introductions Implementation of pediatric vaccines Variance for ecommendation Framework: mRNA COVID-19 vaccine in young children ages 6 months - 5 years Variance for Brobesse Control and Prevention Carens for Medicare and Medical Services Coronavirus Disease 2019 Vorter to Recommendations Framework Condo Drug Administration Coronavirus disease control and Prevention Carens for Medicare and Medical Services Coronavirus disease 2019 Vorter to Recommendations Framework Coronavirus disease 2019	